A Phase II Open-Label Randomized Controlled Pre-Surgical Feasibility Study of Antibiotic Combinations in Early Breast Cancer – ABC2

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517993-94-00

Acronym

ABC2

Enrollment

Registered

2024-11-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Reduction in Ki67 expression in post-treatment tumor core biopsies compared to pre-treatment tumor core biopsies (from the same patient). Post-treatment samples will also be compared with untreated samples.

Interventions

DRUGAZITROMICINA ZENTIVA 500 mg compresse rivestite con film

DRUGBassado 100 mg compresse

DRUGCEBION

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Reduction in Ki67 expression in post-treatment tumor core biopsies compared to pre-treatment tumor core biopsies (from the same patient). Post-treatment samples will also be compared with untreated samples.	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026